DISCLOSURE STATEMENT:

It is our intent that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of the facts. It is not assumed any potential conflicts will have an adverse impact on these presentations. It remains for the audience to determine whether the speaker’s outside interest may reflect a possible bias, either the exposition or the conclusions presented.                                                                                                               

The following presenter(s) have disclosed they have a relevant financial relationship with an ineligible company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients and have disclosed that a conflict of interest exists with the presentation. An explanation of how the conflict is being mitigated is listed below.

Bradley Gelfand, PhD has disclosed that he is co-founder of DiceRx which currently has no assets and all relevant financial relationships have been mitigated.

All other planning committee members and presenters have disclosed they have no relevant financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients and have disclosed that no conflict of interest exists with the presentation/educational event.

FACULTY

Tal Ben-Ami, MD, Head of Pediatric Hematology-Oncology Unit, Kaplan Medical Center, Rehovot, Israel 

Kenneth Chen, MD, Center for Cancer and Blood Disorders, University of Texas- Southwestern

Bradley Gelfand, PhD, Associate Professor of Ophthalmology, University of Virginia 

Jessica Hatton, MS, CGC, Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD 

David Huntsman, MD, Director of Ovcare & Distinguished Scientist, Deputy Department Head, BC Cancer Agency Research Centre 

Masahiko Kuroda, MD, PhD, Department of Molecular Pathology, Tokyo Medical University, Tokyo, 160-8402, Japan 

Randy Larsen, MS, St. Jude Graduate School of Biomedical Science 

Orli Michaeli, MD, Division of Hematology/Oncology, Schneider Children’s Medical Center of Israel 

Shin-ichiro Ohno, PhD, Department of Molecular Pathology, Tokyo Medical University, Tokyo, 160-8402, Japan 

Kris Ann Schultz, MD, International PPB/DICER1 & OTST Registries, Cancer and Blood Disorders, Children’s Minnesota 

Mona Wu, PhD, Postdoctoral Research Fellow, Amatruda Lab, Division of Hematology-Oncology, Cancer and Blood Disease Institute, University of Southern California/ Children’s Hospital of Los Angeles